GlassScriptPhysician profile
Tina Renee Foster
NPI 1942972146
$4,070.81
in general payments reported to CMS, 2019-2025
21 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $667 · 2023: $1,389 · 2024: $866 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.97 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,001.14 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $571.78 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $451.20 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $349.04 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $335.70 | 2022-2025 | Fanapt, Hetlioz |
| Indivior INC. | $200.03 | 2023-2025 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $199.36 | 2022-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $154.80 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $141.55 | 2022-2025 | Auvelity |
| Lundbeck LLC | $135.58 | 2022-2024 | Rexulti |
| Abbvie INC. | $105.88 | 2023-2025 | |
| Braeburn INC. | $84.34 | 2023-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $71.93 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $63.55 | 2023-2025 | Secuado, Xelstrym |
| Ironshore Pharmaceuticals INC. | $56.76 | 2022-2023 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $47.36 | 2022-2023 | Azstarys |
| Avanir Pharmaceuticals, INC. | $29.99 | 2022 | |
| Glaxosmithkline, LLC. | $29.79 | 2022-2023 | Trelegy Ellipta |
| Biogen, INC. | $16.01 | 2025 | Skyclarys |
| Tris Pharma INC | $13.05 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.